AVEO Pharmaceuticals announced the initiation of a Phase 1b/2a clinical trial of AV-951 as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC).  The company launched the Phase 1b portion to evaluate continuous, escalating daily doses of oral AV-951 over four weeks in approximately 21 patients with recurrent or progressive NSCLC, or who are non-responsive to standard therapy.  Safety, tolerability and maximum tolerated dose (MTD) will be observed as the primary outcomes of the Phase 1b portion of this Phase 1b/2a trial. Once MTD is determined, the subsequent Phase 2a portion of the trial will evaluate over eight weeks the overall response rate to daily dosing with AV-951 in 21-41 patients with recurrent, progressive or non-responsive NSCLC and no prior exposure to anti-angiogenic therapy.

AV-951 is a novel, highly potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, exhibiting picomolar inhibitory activity against all three receptors.

For more information visit www.aveopharma.com.